Literature DB >> 22939906

Human papillomavirus, lichen sclerosus and penile cancer: a study in Belgium.

K W M D'Hauwers1, C E Depuydt, J J Bogers, J C Noel, P Delvenne, E Marbaix, A R T Donders, W A A Tjalma.   

Abstract

PURPOSE: The prevalence of penile cancer varies between 1.5 (industrialized countries) and 4.5 per 100,000 men (non-industrialized countries). Predominant histological subtype is squamous cell carcinoma (SCC). Human papillomavirus (HPV) is found in 40-46% of cases: penile cancer is considered to behave as vulvar cancer. Non HPV related risk factors are lack of circumcision, phimosis, chronic inflammation, and smoking. The role of lichen sclerosus (LS) is unclear. Clinical diagnosis is difficult and treatment often mutilating. Preventive measures can be taken since the risk factors are known: the use of the prophylactic HPV vaccines may contribute. We measured the prevalence of HPV and LS in penile cancer in Belgium.
MATERIALS AND METHODS: We found 76 samples of penile lesions in the archives of the departments of Histology of four university hospitals in Belgium. Real-time PCR of type-specific HPV DNA was performed targeting 18 HPV types. PRINCIPAL
RESULTS: Patients with penile intraepithelial neoplasia (PeIN) were 56.1 years of age: patients with invasive penile cancer (IPC) 68.5 (p=0.009). Fifty-five samples (55/76) were adequate for HPV targeting. Overall HPV DNA was 70.9%: 89.5% in samples of PeIN (n=19) and 61.1% in samples of IPC (n=36). Invasive penile cancer samples were less likely to be HPV infected (p=0.028). HPV 16 was most prevalent: 48.3%: 20% PeIN, and 28.3% IPC. HPV DNA of the types, included in the prophylactic vaccines, was found in 33% of PeIN and 31.7% of IPC samples. Thrice, low risk HPV (lrHPV) types 6 (1 IPC) and 11 (1 PeIN, 1 IPC) were solely present. There was no difference in the presence of LS between HPV positive and HPV negative samples (p=0.944).
CONCLUSIONS: Prevalence of HPV DNA in penile lesions in Belgium is high. However, the prophylactic vaccines may contribute to primary prevention of only a subset of cases. The role of LS remains unclear.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22939906     DOI: 10.1016/j.vaccine.2012.08.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  The analysis of human papillomavirus DNA in penile cancer tissue by in situ hybridization.

Authors:  Daiji Takamoto; Takashi Kawahara; Jun Kasuga; Takeshi Sasaki; Masahiro Yao; Yasushi Yumura; Hiroji Uemura
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

Review 2.  Male genital premalignant dermatoses.

Authors:  Oliver Kayes; Majid Shabbir; Suks Minhas
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

3.  Canadian Urological Association guideline on the care of the normal foreskin and neonatal circumcision in Canadian infants (full version).

Authors:  Sumit Dave; Kourosh Afshar; Luis H Braga; Peter Anderson
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

4.  Prevalence of human papillomavirus in penile malignant tumors: viral genotyping and clinical aspects.

Authors:  Isaura Danielli Borges de Sousa; Flávia Castello Branco Vidal; João Paulo Castello Branco Vidal; George Castro Figueira de Mello; Maria do Desterro Soares Brandão Nascimento; Luciane Maria Oliveira Brito
Journal:  BMC Urol       Date:  2015-02-24       Impact factor: 2.264

Review 5.  Male genital lichen sclerosus.

Authors:  Christopher Barry Bunker; Tang Ngee Shim
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

6.  The relationship between human papillomavirus and penile cancer over the past decade: a systematic review and meta-analysis.

Authors:  Yong-Bo Yu; Yong-Hua Wang; Xue-Cheng Yang; Yang Zhao; Mei-Lan Wang; Ye Liang; Hai-Tao Niu
Journal:  Asian J Androl       Date:  2019 Jul-Aug       Impact factor: 3.285

Review 7.  Premalignant male genital dermatoses.

Authors:  Rochit Rajesh Singhal; Trusha Manoj Patel; Kira Antony Pariath; Rita Vipul Vora
Journal:  Indian J Sex Transm Dis AIDS       Date:  2019 Jul-Dec

8.  Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.

Authors:  Steven Simoens; Andre Bento-Abreu; Barbara Merckx; Sophie Joubert; Steve Vermeersch; Andrew Pavelyev; Stefan Varga; Edith Morais
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

9.  The presence of human papillomavirus and Epstein-Barr virus in male Chinese lichen sclerosus patients: a single center study.

Authors:  Yumeng Zhang; Qiang Fu; Xiong Zhang
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

10.  Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature.

Authors:  Julianne Peabody; Pavan Muttil; Bryce Chackerian; Ebenezer Tumban
Journal:  Papillomavirus Res       Date:  2017-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.